CRA was retained by plaintiff in a matter involving the alleged infringement of patents associated with extended-release formulations of a pain management product. CRA reviewed existing and similar licenses for their relevance to determining a royalty range for the hypothetical negotiation between willing parties. CRA then conducted a Georgia-Pacific analysis to provide an opinion on the reasonable royalty assuming the patents were valid and infringed. A key consideration was how extended-release technologies enabled a long-acting formulation that became widely used and favored over short-acting versions.
Overview of IP litigation in the US involving Chinese companies
This underscores China’s growing commitment to address intellectual property (IP) disputes with foreign entities. While litigators and companies are evaluating...